Skip to main content
OpenTrials
Completed

NCT Number: NCT07378579

An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001

This a phase 1, partially blinded, randomized, crossover study to determine the pharmacokinetics (PK) and QT/QTc interval of study drug (ESK-001) in healthy volunteer participants,

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Fortrea CRU

Daytona Beach, Florida, 32117, United States

About this study

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4) (A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male and female subjects aged between 18 and 55 years, inclusive. Body mass index between ≥18.0 and ≤32.0 kg/m2, inclusive, and a minimum body weight of 45 kg.
  • Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
  • In good health, determined by no clinically significant findings from medical history, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations, and from the physical examination at screening or check-in, as assessed by the investigator (or designee).
  • Serum sodium, potassium, calcium, and magnesium levels are within the normal range at screening and check-in-

Exclusion criteria

  • Positive hepatitis panel and/or positive human immunodeficiency virus test, hepatitis B surface antigen, or hepatitis C antibodies.
  • Alanine aminotransferase or aspartate aminotransferase >1.5 times the upper limit of normal, at screening or check-in.
  • History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).
  • Surgery within the past three months prior to the first study drug administration determined by the principal investigator to be clinically relevant.
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed).
  • History of Gilbert's syndrome or cholecystectomy surgery.

Treatment and study plan

ESK-001

Drug

Single oral dose of ESK-001 in participants

Moxifloxacin (400 mg)

Drug

positive control

Placebo

Drug

ESK-001-matched placebo

Primary outcomes

  1. Change from baseline in placebo-adjusted QTcF (∆∆QTcF)

    Time frame: 24 hours

Secondary outcomes

  1. Change from baseline in ECG parameter ΔHR

    Time frame: 24 hours

  2. Change from baseline in ECG parameter Δ PR interval

    Time frame: 24 hours

  3. Change from baseline in ECG parameter ΔQRS duration

    Time frame: 24 hours

  4. Change from baseline in ECG parameter ΔQTc interval

    Time frame: 24 hours

  5. Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation

    Time frame: Up to 22 Days

  6. Number of clinically significant changes in clinical laboratory values, vital signs, ECGs, and physical examinations

    Time frame: Up to 22 Days

  7. Composite of pharmacokinetic (PK) parameter Vz/F for ESK-001 and metabolites

    Time frame: 24 hours

  8. Composite of pharmacokinetic (PK) parameter Cmax for ESK-001 and metabolites

    Time frame: 24 hours

  9. Composite of pharmacokinetic (PK) parameter tmax for ESK-001 and metabolites

    Time frame: 24 hours

  10. Composite of pharmacokinetic (PK) parameter CL/F for ESK-001 and metabolites

    Time frame: 24 hours

Sponsors and collaborators

Lead sponsor

Alumis Inc

Industry

Registry information

Official study title

A Phase 1, Partially Blinded, Randomized, Crossover Study to Evaluate the Pharmacokinetics and QT/QTc Interval of ESK-001 Compared to Placebo and Moxifloxacin in Healthy Subjects

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Jan 30, 2026
Registry last updated
Jan 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.